Advanced Solid Malignancies
Conditions
Keywords
OB318, Advanced Solid Malignancies, Antrodia cinnamomea, Antrodia camphorata
Brief summary
The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in patients with advanced solid malignancies.
Interventions
DRUGOB318 capsule
Oral qd, at least 30 minutes before breakfast
Sponsors
Oneness Biotech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients of age ≥20 years 2. Pathologically or cytologically confirmed advanced solid tumors for which standard therapy proven to provide clinical benefit does not exist or is no longer effective; the diagnosis of hepatocellular carcinoma (HCC) made according to the imaging specified in the American Association for the Study of Liver Diseases (AASLD) 2018 is acceptable. 3. Evaluable disease, at least one measurable untreated target lesion on imaging by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria. 4. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2. 5. Life expectancy ≥ 3 months. 6. If history of brain metastases treated with radiation therapy, radiation therapy is required to be completed at least 3 months prior to enrolment and metastasis achieve stable disease (SD) since radiation completion. 7. Must have recovered from toxicities of previous anti-cancer treatments to NCI-CTCAE grade 1 or lower, except for alopecia. 8. Laboratory values at screening of: * Absolute neutrophil count ≥ 1,500 /mm3; * Platelets ≥ 75,000 /mm3; * Hemoglobin (Hb) ≥ 8.5 g/dL; * Total bilirubin ≤2.0 mg/dL; * AST (SGOT) ≤ 3 × ULN (upper limit of normal); * ALT (SGPT) ≤ 3 × ULN; * Serum creatinine ≤1.5 mg/dL or a measured creatinine clearance ≥ 60 mL/min. 9. Patients with primary liver cancer or hepatic metastasis are eligible to enroll, provided that, at screening, the following criteria are met: * Total bilirubin ≤2.0 mg/dL; * AST and ALT ≤ 5 × ULN; * Child-Pugh Class A; * Patients with a history of esophageal bleeding have varices that have been sclerosed or banded and no bleeding episodes have occurred during the prior 6 months. 10. Female patients must be either of non-childbearing potential, i.e. surgically sterilized or one year post-menopausal; or, if of childbearing potential, confirmed not pregnant at screening and must use adequate contraceptive precautions (as per investigator) during the entire treatment period of this study and for 6 months after exiting from the study. 11. Male patients with female partners of childbearing potential must be willing to use a reliable form of contraception (as per investigator), from screening until 6 months after exiting from the study. 12. Given signed and dated written informed consent and willing/able to comply with all protocol required visits/procedures
Exclusion criteria
1. Primary major surgery (of the brain, chest, abdomen and/or pelvis requiring general anesthesia) \< 4 weeks prior to the planned first study treatment day. 2. Lactating or pregnant women or plans to be become pregnant. 3. Except for alopecia, any drug-related AE from any previous treatments not recovered to grade 1 or less prior to the planned first study treatment day. 4. With active systemic infections, active and clinically significant cardiac diseases, active gastrointestinal diseases, active pulmonary diseases, or medical conditions that may significantly affect adequate absorption of investigational product, eg., bad nutrition, proteinuria, etc.. 5. Previous malignancy, except for basal-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix, unless the tumor was treated with curative intent more than 2 years prior to study entry. 6. Known allergic to Antrodia cinnamomea and its related substances, including mannitol, gelucire, silicon dioxide and gelatin. 7. History of autoimmune disease. 8. Taking anti-coagulant or anti-platelet drugs (eg aspirin, Coumadin, ginko, clopidogrel). 9. Use of any investigational agents or non-registered product within 4 weeks of baseline. 10. Known human immunodeficiency virus (HIV) positivity. 11. With conditions, judged by the investigator, as unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicities (DLTs) of OB318 | 28 days | NOTE: DLT is defined as any grade 3 or above toxicity by NCI-CTCAE version 4.03, as determined by the investigator and sponsor, to be at least possibly related in causality to the administered investigational product OB318 and will be observed during the 4 weeks of treatment for patients in the dose escalation phase. |
| Maximum tolerated dose (MTD) of OB318 | 28 days | NOTE:- MTD is defined as the prior dose level below the dose level at which 2/3 or 2/6 subjects suffer dose limiting toxicity (DLT) in the dose escalation phase |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in laboratory safety tests (hematology, biochemistry, urinalysis) from baseline | up to 84 days | Laboratory safety tests will be performed at screening, baseline, Day 14 and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, lab tests will be done before each 28 days cycle. |
| Incidence of Adverse Events (AEs) | up to 84 days | — |
| Incidence of Serious Adverse events (SAEs) | up to 84 days | — |
| Incidence of toxicities ≥ grade 3, according to NCI-CTCAE version 4.03, related to OB318, during extension phase | up to 84 days | — |
| Characterization of toxicities ≥ grade 3, according to NCI-CTCAE version 4.03, related to OB318, during extension phase | up to 84 days | — |
| Changes in physical examination from baseline | up to 84 days | Physical examination will be performed at screening, baseline, and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, physical examination will be done at last day of each cycle. |
| Changes in vital signs from baseline | up to 84 days | Vital signs will be performed at each study visit. |
| Changes from baseline in Electrocardiogram (ECG) results (QRS, QT, QTc, RR intervals) | up to 84 days | Electrocardiogram (ECG) is conducted at screening, baseline, Day 14 and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, ECG will be conducted at the same time. |
| Tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at the end of the | up to 84 days | Imaging for tumor assessment will be made at screening, at the end of the treatment for the dose escalation and at the end of Cycle 2 for the extension phase. |
| Pharmacokinetic parameters- Cmax | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- AUC from time zero to the last quantifiable concentration | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- AUC from time zero extrapolated to infinity | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters-CL/F | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters-Vz/F | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters-Tmax | Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Terminal elimination half-life | Day 1 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Terminal elimination rate constant | Day 1 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters-Ctrough | Day 27 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 ; Day 7 and Day 14 of Cycle additionally for dose level 1 only | — |
| Pharmacokinetic parameters- Cmin,ss | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Cmax,ss | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Cavg,ss | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- AUC(0-24h) | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- CLss/F | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Vz,ss/F | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Tmax,ss | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- FI | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
| Pharmacokinetic parameters- Rac | Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 | — |
Countries
Taiwan
Contacts
PRINCIPAL_INVESTIGATORChing-Liang Ho
Tri-Service General Hospital (TSGH)
Outcome results
None listed